Agilent Technologies, Inc. A
Composite 52/100; the shares have moved about 37% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 29/100 — a moderate mark against it.
Balance-sheet strength ranks 67/100 — a moderate point in its favour. Quality ranks 64/100 — a moderate point in its favour. Momentum ranks 62/100 — a slight point in its favour.
Growth ranks 29/100 — a moderate mark against it. Valuation ranks 34/100 — a moderate mark against it. Income ranks 41/100 — a slight mark against it.
What the company does Agilent Technologies provides application-focused solutions for life sciences, diagnostics, and applied chemical markets. Its segments include Life Sciences and Diagnostics, Agilent CrossLab (services and consumables), and Applied Markets. Key offerings span liquid chromatography, mass spectrometry, genomics, and laboratory software.
Key financials Agilent reports strong profitability with ROE 21.3%, ROA 8.6%, and ROCE 15.6%. Margins are healthy: gross 52.6%, operating 23.7%, net 19.6%. Revenue grew 6.7% but EPS declined -65.5%. Debt/Equity is 0.54 with interest coverage of 16.05x and current ratio 2.05.
Stock health SIDERAVIA scores show average quality (66.8) but weak growth (30.3) and rich valuation (29.6). Momentum is positive over 3m 11.23%, 6m 26.48%, and 12m 20.27%, though down -8.44% from its 52-week high. RSI(14) is neutral at 52.80.
Price vs fair value The stock trades at a **discount of 6.80%** versus the analyst mean target of 160.11. - Agilent expanded non-GAAP margins by 320 bps, raising questions about repeatability (Aug 29). - New product launches like the Cary 635 FTIR Spectrometer may support long-term growth (Sep 1). - Laboratory modernization trends benefit Agilent’s applied markets segment (Aug 31).
Looking forward Forward P/E is 22.08 and PEG is 0.63, suggesting potential value relative to growth. However, weak EPS growth (-65.5%) and high valuation percentiles (29.6) temper enthusiasm. Momentum remains supportive but hinges on margin sustainability and execution in diagnostics and applied markets.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.